AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
update
/
details

SOPHiA GENETICS and AstraZeneca Partner to Expand Global Access to Liquid Biopsy Testing

NextEdge Admin

10 Sep 2024

2 min 16 sec

SOPHiA GENETICS , a cloud-native healthcare technology leader in data-driven medicine, has announced a significant milestone in the global rollout of the liquid biopsy test MSK-ACCESS®, powered by SOPHiA DDM™, following its initial launch in October 2023. In partnership with AstraZeneca (LSE/STO/Nasdaq: AZN), SOPHiA GENETICS will expand the test’s availability to 20 locations worldwide within the next 12 months.

Liquid biopsy testing, which isolates cell-free DNA (cfDNA) from blood plasma to detect circulating tumor DNA (ctDNA), offers a less invasive alternative to traditional solid tumor testing. This method simplifies patient monitoring and speeds up clinical decision-making, especially when traditional biopsies are not feasible. MSK-ACCESS®, originally developed by Memorial Sloan Kettering Cancer Center, is now decentralized through SOPHiA DDM™'s cloud-based platform, combining advanced algorithms with MSK’s expertise in cancer genomics.

The partnership between SOPHiA GENETICS and AstraZeneca aims to demonstrate the benefits of liquid biopsy testing as a complement to solid tissue analysis. Through a real-world evidence study, they will evaluate the operational and clinical advantages of this method in various labs. Already, 14 major healthcare institutions globally, including renowned cancer centers and laboratories, have adopted MSK-ACCESS® powered with SOPHiA DDM™.

This collaboration seeks to address global health disparities, accelerate cancer research, and improve access to data-driven treatment options worldwide. Kristina Rodnikova, Head of Global Oncology Diagnostics at AstraZeneca, emphasized the commitment to expanding liquid biopsy expertise globally.